A Phase ?, Randomized, Double-Blind, Placebo-control, Dose-Finding, Efficacy and Safety of YY-162 in Patients with ADHD(Attention Deficit Hyperactivity Disorder)

Start Date29 Dec 2011

Sponsor / Collaborator-

NCT01536210 / CompletedPhase 3

Randomized, Double-Blind, Placebo-control, Multicenter Study, the Efficacy and Safety of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD(Attention Deficit Hyperactivity Disorder)in 8 Weeks

This study will evaluate clinical efficacy and safety of treatment with YY-162 in children with ADHD.

Start Date01 Dec 2011

Sponsor / Collaborator

Yuyu Pharma, Inc.

NCT01201187 / CompletedPhase 3

Randomized, Double-Blind, Placebo-control, Multicenter Study, the Efficacy and Safety of Combination of Ginkgo Extract and Ginseng Extract(YY-162) in Children With ADHD(Attention Deficit Hyperactivity Disorder)in 8 Weeks

This study will evaluate clinical efficacy and safety of treatment with YY-162 in children with ADHD

Start Date01 Mar 2010

Sponsor / Collaborator

Yuyu Pharma, Inc.

100 Clinical Results associated with YY-162

100 Translational Medicine associated with YY-162

100 Patents (Medical) associated with YY-162

Literatures (Medical) associated with YY-162

01 Mar 2014·Food and Chemical ToxicologyQ2 · MEDICINE

YY162 prevents ADHD-like behavioral side effects and cytotoxicity induced by Aroclor1254 via interactive signaling between antioxidant potential, BDNF/TrkB, DAT and NET

Q2 · MEDICINE

Article

Author: Lee, Jeong Hyun ; Shin, Seung Woo ; Chae, Jong Seok ; Jung, Jong Ho ; Shin, Eun-Joo ; Jang, Choon-Gon ; Ha, Jong Ryul ; Kim, Hyoung-Chun ; Ko, Sung Kwon ; Nam, Yunsung ; Lim, Yong Kwang ; Jeong, Ji Hoon

Methylphenidate (MP) has become the primary drug of choice for treatment of attention-deficit/hyperactivity disorder (ADHD). However, its psychotropic effects severely hamper long-term clinical use. We evaluated the effects of YY162, which consists of terpenoid-strengthened Ginkgo biloba and ginsenoside Rg3, on the ADHD-like condition induced by Aroclor1254, because both components have been suggested to modulate oxidative stress, dopaminergic neurotransmission, and brain-derived neurotrophic factor (BDNF) signaling, which may be critical targets for understanding the pathogenesis of ADHD. YY162 attenuated the increase in reactive oxygen species (ROS) and decrease in BDNF levels induced by Aroclor1254 in SH-SY5Y neuroblastoma cells. YY162 significantly attenuated Aroclor1254-induced ADHD-like behavior and oxidative stress in ICR mice. Furthermore, YY162 attenuated reductions in p-TrkB, BDNF, dopamine transporter (DAT) and norepinephrine transporter (NET) expression. These attenuating effects of YY162 were comparable to those of MP. Importantly, K252a, a TrkB antagonist, counteracted the protective effects of YY162. Our results suggest that YY162 possesses significant protective activities against ADHD-like conditions with negligible behavioral side effects, and that interactive signaling between antioxidant potential and BDNF/TrkB receptor for the positive modulation of the DAT and NET is important for YY162-mediated neuroprotective activity.

100 Deals associated with YY-162

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Attention Deficit Disorder With Hyperactivity	Phase 3	-	Yuyu Pharma, Inc.	-
Behavioural disorders	Preclinical	KR	Yuyu Pharma, Inc.	01 Mar 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

YY-162

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation